Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Viet Nam Pharmaceutical - JSC's quarterly other current liabilities
increased
from Sep. 2025 (₫59,413 Mil) to Dec. 2025 (₫74,873 Mil) and
increased
from Dec. 2025 (₫74,873 Mil) to Mar. 2026 (₫82,573 Mil).
Viet Nam Pharmaceutical - JSC's annual other current liabilities
declined
from Dec. 2023 (₫54,732 Mil) to Dec. 2024 (₫49,641 Mil) but then
increased
from Dec. 2024 (₫49,641 Mil) to Dec. 2025 (₫74,873 Mil).
Viet Nam Pharmaceutical - JSC Other Current Liabilities Related Terms
Viet Nam Pharmaceutical - JSC Other Current Liabilities Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viet Nam Pharmaceutical - JSC Other Current Liabilities Chart
Viet Nam Pharmaceutical - JSC Other Current Liabilities Calculation
The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.
What does a Other Current Liabilities of ₫82,573 Mil mean?
Viet Nam Pharmaceutical - JSC (HSTC:DVN) has a Other Current Liabilities of ₫82,573 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Viet Nam Pharmaceutical - JSC.
Is Viet Nam Pharmaceutical - JSC's Other Current Liabilities too high?
Viet Nam Pharmaceutical - JSC's current Other Current Liabilities is ₫82,573 Mil. Overall, Viet Nam Pharmaceutical - JSC has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Viet Nam Pharmaceutical - JSC's Other Current Liabilities compare to ZTS and UTHR?
Viet Nam Pharmaceutical - JSC's Other Current Liabilities of ₫82,573 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Viet Nam Pharmaceutical - JSC. Viet Nam Pharmaceutical - JSC's current Other Current Liabilities is ₫82,573 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viet Nam Pharmaceutical - JSC stock overvalued right now?
Based on GuruFocus' analysis, Viet Nam Pharmaceutical - JSC (HSTC:DVN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫22,079.33, compared to a current price of ₫19,000.00 — trading 13.9% below its estimated fair value. The current Other Current Liabilities is ₫82,573 Mil. Viet Nam Pharmaceutical - JSC's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Viet Nam Pharmaceutical - JSC (HSTC:DVN), the current Other Current Liabilities is ₫82,573 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viet Nam Pharmaceutical - JSC (HSTC:DVN) Overvalued in 2026?
Based on GuruFocus' analysis, Viet Nam Pharmaceutical - JSC stock appears to be undervalued.
The current stock price of ₫19,000.00 is trading 13.9% below its estimated GF Value™ of ₫22,079.33.
GuruFocus considers Viet Nam Pharmaceutical - JSC to be Modestly Undervalued.
Key valuation signals for HSTC:DVN:
Other Current Liabilities: ₫82,573 Mil
GF Value™: ₫22,079.33 vs. price of ₫19,000.00 (13.9% below fair value)
No single metric tells the full story. See the HSTC:DVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viet Nam Pharmaceutical - JSC Business Description
Viet Nam Pharmaceutical Corp - JSC is engaged in the manufacturing of drugs. The company provides testing services for drugs and medicinal ingredients.
80GF Score
Get the complete analysis for HSTC:DVN
Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HSTC:DVN has been successfully added to your 
